Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 399.5 DKK -1.03% Market Closed
Market Cap: 92.6B DKK

Wall Street
Price Targets

GMAB Price Targets Summary
Genmab A/S

Wall Street analysts forecast GMAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GMAB is 2 278.38 DKK with a low forecast of 1 445.31 DKK and a high forecast of 3 118.5 DKK.

Lowest
Price Target
1 445.31 DKK
3% Upside
Average
Price Target
2 278.38 DKK
63% Upside
Highest
Price Target
3 118.5 DKK
123% Upside
Genmab A/S Competitors:
Price Targets
DSGN
Design Therapeutics Inc
45% Upside
300601
Shenzhen Kangtai Biological Products Co Ltd
29% Upside
HPHA
Heidelberg Pharma AG
367% Upside
MNPR
Monopar Therapeutics Inc
39% Upside
6160
Beigene Ltd
10% Upside
LYTIX
Lytix Biopharma AS
168% Upside
BPMC
Blueprint Medicines Corp
40% Upside
ATYR
aTyr Pharma Inc
368% Upside

Revenue
Forecast

Revenue Estimate
Genmab A/S

For the last 8 years the compound annual growth rate for Genmab A/S's revenue is 36%. The projected CAGR for the next 3 years is 14%.

36%
Past Growth
14%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Genmab A/S

For the last 8 years the compound annual growth rate for Genmab A/S's operating income is 27%. The projected CAGR for the next 3 years is 19%.

27%
Past Growth
19%
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Genmab A/S

For the last 8 years the compound annual growth rate for Genmab A/S's net income is 27%. The projected CAGR for the next 3 years is 12%.

27%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GMAB's stock price target?
Price Target
2 278.38 DKK

According to Wall Street analysts, the average 1-year price target for GMAB is 2 278.38 DKK with a low forecast of 1 445.31 DKK and a high forecast of 3 118.5 DKK.

What is Genmab A/S's Revenue forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Genmab A/S's revenue is 36%. The projected CAGR for the next 3 years is 14%.

What is Genmab A/S's Operating Income forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for Genmab A/S's operating income is 27%. The projected CAGR for the next 3 years is 19%.

What is Genmab A/S's Net Income forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for Genmab A/S's net income is 27%. The projected CAGR for the next 3 years is 12%.

Back to Top